Folylpoly-γ-gluatmate synthetase (FPGS) catalyzes the polyglutamylation and thus intracellular retention of folates and antifolates (e.g. methotrexate; MTX) through the addition of multiple glutamate equivalents to their γ -carboxyl residue. Since polyglutamylation of antifolates is crucial for their pharmacological activity in leukemia, loss of FPGS function results in decreased cellular levels of polyglutamylation-dependent antifolates and consequent drug resistance. Whereas resistance to pulse exposure to antifolates is frequently associated with loss of FPGS activity, the underlying molecular mechanism remains elusive. Here we explored the molecular basis of antifolate-resistance in human MTX-resistant leukemia cell lines displaying marked loss of FPGS activity. We demonstrate that these MTX-resistant cells exhibit impaired splicing of FPGS mRNA based on intron retention and/or exon skipping, thereby resulting in loss of FPGS function due to premature translation termination.
Introduction
Folates are essential vitamins that serve as one-carbon donors in a variety of biosynthetic pathways including the de novo biosynthesis of purines and thymidylate, mitochondrial protein synthesis and amino acid conversion 1 . Folate analogues (i.e. antifolates) exert their cytotoxic activity via potent inhibition of various folate-dependent enzymes that mediate de novo nucleotide biosynthesis, block DNA replication and hence induce cell death 2 .
Consequently, antifolates are currently used as important anti-cancer drugs for the treatment of various human malignancies; in this respect, methotrexate (MTX), the first antifolate introduced nearly 60 years ago, achieved remarkable remissions in acute lymphoblastic leukemia (ALL) 3 . MTX and novel antifolates including pemetrexed (Alimta) and raltitrexed (Tomudex) are currently used for the treatment of various human cancers including ALL, lymphomas, breast cancer, osteosarcoma, colorectal cancer, malignant pleural mesothelioma and choriocarcinoma. Antifolates are also used, particularly upon a low dose regimen, for the treatment of non-neoplastic disorders including rheumatoid arthritis, psoriasis and Crohn's disease. Currently, antifolates are also used for the treatment of parasitic diseases and fungal diseases such as malaria and Pneumocystis Carinii pneumonia, respectively.
Folate cofactors and antifolates are divalent anions and hence require specific membrane transporters and receptors for their translocation across biological membranes 4 .
These transport routes include the proton-coupled folate transporter (PCFT/SLC46A1), the reduced folate carrier (RFC/SLC19A1) and folate receptors (summarized in Assaraf 5 and Zhao and Goldman 6 ). Once taken up into cells, folates and antifolates undergo polyglutamylation catalyzed by folylpolyglutamate synthetase (FPGS) which adds up to 10 glutamate residues, one at a time, to the γ -carboxyl residue of folates and antifolates 7, 8 . This unique metabolism renders folates and antifolates polyanions which can no longer be effluxed out of cells, thereby resulting in enhanced intracellular retention. Since polyglutamylation plays a key role in cellular retention of antifolates and thus increases their cytotoxic activity, loss of FPGS activity is an established mechanism of resistance to polyglutamylationdependent antifolates in vitro and in vivo [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . This phenomenon was observed in various malignant cell lines selected for resistance to intermittent exposure to high dose polyglutamatable antifolates including MTX, raltitrexed and pemetrexed [9] [10] [11] [12] [13] [14] [15] [16] [17] 20 . Using this modality of pulse drug exposure, the vast majority of antifolate-resistant tumor cell lines displayed a 90-99% loss of FPGS activity, frequently in the absence of any substantial
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In the clinic, high dose (HD) MTX is a major component in all contemporary treatment protocols for ALL and much is known about the cellular and molecular pharmacology of MTX in ALL. Impaired polyglutamylation is an established mechanism of resistance to MTX in T-lineage ALL as opposed to c/preB-ALL 18 . The ability of lymphoblasts to form and accumulate MTX polyglutamates is a well recognized determinant of the anti-leukemic effects of MTX in vivo 19, 22 , and was therefore shown to be an important prognostic factor positively predicting curative chemotherapy that contains MTX 19 .
Moreover, Kager et. al 23 showed that 42-44 hr after administration of MTX (0.8 g/m 2 ), T-ALL bone marrow cells displayed a poor formation of long-chain (Glu 4-7 ) MTX polyglutamates (355 pmol/10 9 cells), whereas MTX polyglutamylation in hyperdiploid (lower than 50 chromosomes) B-cell leukemia was 9-fold higher (3,170 pmol/10 9 cells). Hence, the initial aim of the current study was to explore the post-transcriptional mechanisms involved in the frequent loss of FPGS activity in antifolate-resistant tumor cell lines, particularly when no decrease in FPGS mRNA levels is observed. Toward this end, we here discovered a novel molecular mechanism underlying loss of FPGS activity in antifolate-resistant human ALL cell lines that is based on impaired FPGS splicing including intron retention and/or exon skipping.
Moreover, defective FPGS splicing was also identified in bone marrow and peripheral blood samples obtained from ALL patients at diagnosis and at relapse, the latter of which occurring after HD MTX-containing chemotherapy. This novel modality of antifolate-resistance is based upon impaired FPGS splicing as reflected in the retention of introns and/or skipping of exons, thereby resulting in a frame-shift in the open reading frame and premature translation termination leading to loss of FPGS function.
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Materials and Methods

Tissue Culture
The human T-cell lymphocytic leukemia lines CCRF-CEM and Molt-4 as well as their established and maintained as previously described 14 .
Antifolate growth inhibition assay
Detailed in Supplemental data.
[
H]MTX transport assay
Detailed in Supplemental data
FPGS activity assay
Detailed in Supplemental data
Semi-quantitative RT-PCR Analysis of Various Genes
Cells (1x10 7 ) from the mid-log phase of growth were harvested by centrifugation, washed with phosphate buffered saline (PBS) and total RNA was isolated using the Tri-Reagent kit according to the instructions of the manufacturer (Sigma) and treated with DNase (Promega).
A portion of total RNA (12 μ g in a total volume of 50 μ l) was reverse transcribed using M-MLV (400 units, Promega) in a reaction buffer containing random hexamer primers (Promega), dNTPs (Larova,) and a ribonuclease inhibitor Rnasin (TaKaRa). PCR was performed using 10 pmols of each primer ( Tables 1, 2 
and 3) in 2xReddyMix PCR master
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From mix reaction buffer according to the instructions of the manufacturer (ABgene). Then, the PCR products were resolved on 1% agarose gels containing ethidium bromide. 
DNA Sequencing
Detailed in Supplemental data
Expression
Stable Transfections with hFPGS Expression Constructs
Exponentially growing cells (i.e. CCRF-CEM and CEM-MTX R10 ) were harvested by centrifugation and stably transfected by electroporation (1000µF, 234V) with 10µg of the vectors pcDNA3.1, pIRES2-EGFP, pcDNA3/hFPGS or pIRES/FPGSΔexon10. After 24h of growth at 37°C, cells were exposed to 450 to 600µg/ml active G-418 and single clones were then picked and expanded. Stable transfectants obtained after 4 weeks of G-418 selection were analyzed for FPGS mRNA levels by Northern blots as detailed below and used for further analyses. respectively). DNA sequencing of these long PCR products from MTX R5 P cells revealed that introns 1, 2, 10, 11 and 12 were retained in the FPGS mRNA ( Fig. 1A ; introns 1,2 and 10-12, lanes 2 and 4, respectively). These findings were indicative of defective splicing which could constitute the molecular basis for the loss of FPGS activity in these antifolate-resistant cells.
Northern Blot Analysis.
Detailed in Supplemental data
Leukemia Patient Specimens
To examine the status of global splicing in MTX R5 P cells, we undertook an RT-PCR analysis on an assortment of genes using primers positioned within neighboring exons, thereby allowing for the formation of two distinct fragments that are diagnostic of intron retention.
The different primers used for this PCR analysis and the various possible product sizes are depicted in Table 3 and the PCR products are shown in Fig. 1B (Fig. 1B) , a variety of other genes showed defective splicing; the latter genes included upstream binding transcription factor, UBTF; tumor necrosis factor α , TNFα; glyceraldehyde-3-phosphate dehydrogenase, GAPDH; platelet-derived growth factor, PDGF; RFC, as well as plexin A1. Therefore, at least 50% of the transcripts encoded by these genes contained unspliced introns, thereby corroborating the prominent splicing defect affecting various genes in MTX R5 P cells (Fig. 1C) . To verify the presence and identity of the unspliced introns, DNA sequencing of all aberrant RT-PCR products was undertaken. Sequencing corroborated the presence of the expected introns in the aberrant unspliced PCR products (Table 3 ). These results establish that antifolate-resistance in MTX R5 P cells is associated with a splicing defect that impairs the splicing of multiple genes.
DNA sequencing reveals alternatively spliced FPGS transcripts in CEM-7OH-MTX cells.
To determine whether impaired splicing of the FPGS gene occurs in other antifolate-resistant human leukemia cell lines, we used CEM-7OH MTX and Molt-4-7OH MTX cells which were recently shown to display 98% loss of FPGS activity 14 . These cell lines acquired resistance to 7-OH-MTX, the primary metabolite of MTX. Thus, FPGS cDNAs from these cell lines were first screened for point mutations and splicing alterations by PCR (primers are depicted in Table 1 ) and then sequenced. DNA sequencing of the PCR product obtained with primers EX8-up and EX13-dw (Table 1 ) revealed the existence of two different transcripts differing in the presence or absence of exon 10 ( Fig. 2) . Since the nucleotide signal peaks of the aberrant transcript (i.e. that lacks exon 10) were either equivalent or higher than those of the expected transcript, we hypothesized that this was a major phenotype of alternative splicing. Following this observation, diagnostic primers were specifically designed to PCR amplify FPGS transcripts that contain or lack exon10. Thus, half of the forward primer resides in the 3'-end of exon 9, whereas the other half maps either to the beginning of exon 10 or exon 11 (i.e. primers ex9-10 and ex9-11, respectively; see Table 2 ). PCR performed on both CEM-7OH MTX and Molt-4-7OH MTX cells resulted in high levels of PCR products lacking exon 10 ( Fig. 3A , lanes 3 and 4 as well as 7 and 8), whereas parental cells exhibited residual levels of this exon 10-free product (Fig. 3A, lanes 2 and 6) . PCR performed on these mutants' cDNA resulted in multiple bands ( long. To confirm the presence of intron 10 in some of the FPGS transcripts in these splicing defective cell lines, we designed a diagnostic primer, half of which resides in the 3'-end of
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From exon 10 and the other half on the 5'-end of intron 10 (i.e. primer ex10-int10; see Table 2 ). As evident from Fig. 3B , no visible product is obtained in parental cell lines (Fig. 3B, lanes 1 and   4) , whereas antifolate-resistant cells exhibit the predicted product containing intron 10 ( Fig.   3B, lanes 2 and 4) . DNA sequencing performed on all PCR products confirmed the presence of intron 10. Although FPGS splicing is not completely deficient, we PCR amplified the TNFα gene in order to explore whether or not other genes remain intact. Using the same primer set as in the MTX R5 P cells, we obtained a normal PCR product size of TNFα (Fig.   3C ). 
Northern blot analysis reveals the absence of a principal FPGS transcript in CEM-
ZD1694
. In contrast, the truncated form of FPGS lacking exon 10 had no effect on FPGS activity. Moreover, expressing this truncated form in parental cells failed to alter antifolate sensitivity or the catalytic activity of the endogenous FPGS.
ALL specimens exhibit FPGS exon 12 skipping. To explore the clinical relevance of our current findings of defective FPGS splicing in antifolate-resistant leukemia cell lines, we undertook an initial study aimed at screening for alterations in FPGS splicing in 13 RNA samples previously obtained from 8 ALL patients, five of which were matched samples at diagnosis and relapse. PCR analysis was designed to confirm the presence of all 15 exons and the absence of all introns (excluding introns 4 and 14 which are too long to be amplified using conventional PCR methodology). As depicted in Figure 5A , while using a primer set residing within exons 9 and 13, one bone marrow sample from a relapse ALL patient (sample R1) that underwent HD MTX-containing chemotherapy, exhibited a low molecular weight FPGS transcript (Fig. 5A, lane 3) , that was absent at the time of diagnosis (sample D1, lane 2). DNA sequencing of this PCR product revealed the absence of FPGS exon 12. A second PCR was performed ( Fig. 5B) with the primer ex11-13 ( Table 2 ) which can only anneal to FPGS cDNA lacking exon 12, thereby producing a 250 bp product that is diagnostic of exon 12 skipping. Consistent with the above results, relapse sample R1 exhibited this 250 bp product which was absent at the time of diagnosis (i.e. sample D1), thereby verifying FPGS exon 12 skipping at relapse (Fig. 5B, lanes 2 and 3, respectively) . Moreover, two diagnosis specimens (Fig. 5B, D5 , D8, lanes 10 and 14 respectively) also exhibited low levels of the 250bp product. Hence, of the 8 ALL patient specimens analyzed, 3 harbored FPGS exon 12 skipping that results in premature translation termination.
For
Discussion
The present paper provides the first evidence that aberrant splicing of FPGS mRNA including intron retention and/or exon skipping, results in premature translation termination, loss of FPGS activity and consequent antifolate-resistance in human leukemia cell lines. At the clinical setting, while RNA specimens are not routinely derived at the time of ALL relapse, we were able to study 13 ALL specimens from 8 different patients, 5 of which were matched samples obtained both at the time of diagnosis and at relapse, along with 3 additional diagnosis samples. This preliminary study identified exon 12 skipping in FPGS transcripts both at diagnosis and relapse, thereby suggesting a possible role in the acquisition of ALL resistance to HD MTX (3gr/m2). It is likely that this antifolate resistance factor may contribute, among other potential unknown mechanisms to disease relapse. It should be noted that since chemotherapy of ALL is a sequential combination-based therapy, it is therefore difficult to attribute the specific contribution of a specific drug resistance modality to the patient outcome. However, MTX is currently considered a key drug in the treatment of ALL and MTX resistance may therefore affect patient' s outcome. (Fig. 3A) as well as intron 10 retention; these alterations became dramatic in the antifolate-resistant sublines. Based on these cumulative results, a plausible scenario that can be envisioned is that pre-existing clonal variants displaying some basal, low level of aberrant splicing of FPGS mRNA may exist in the leukemia cell population prior to treatment with MTX. Under antifolate-free growth conditions, these pre-existing variants are relatively infrequent in the general population as they harbor a growth disadvantage due to their inability to efficiently form and accumulate folate polyglutamates, thereby resulting in a contracted intracellular folate pool 10 . However, upon repeated cycles of pulse drug exposure to relatively high concentrations (i.e. clinically relevant) of polyglutamatable antifolates, these rare clones may be rapidly selected out from the general population. This is particularly true as these clones bear a growth advantage under drug selective conditions due to their inability to form antifolate polyglutamates, hence resulting in rapid efflux of antifolate monoglutamates.
MTX undergoes oxidation to its principal metabolite 7-hydroxymethotrexate (7-OHMTX) in the liver by aldehyde oxidase 33 . The plasma concentration of 7-OHMTX can exceed that of MTX, as in osteosarcoma and ALL patients treated with HD MTX, thereby becoming the predominant metabolite 10-12 hr after bolus MTX infusion 34 . Recently we have
shown that MTX and its metabolite 7-OHMTX provoke disparate mechanisms of antifolate resistance in leukemia cells 14 ; hence, whereas continuous exposure to MTX leads to downregulation of RFC expression and markedly impaired drug uptake 11, 14, 35 , exposure to 7-OHMTX brought about a major decrease (~98%) in FPGS activity with no apparent quantitative alteration at the mRNA level 14 . These findings suggest the involvement of FPGS and not RFC in cases of relapse following treatment with MTX, and hence emphasize the burning need to pinpoint the molecular basis of FPGS-based antifolate resistance and its potential overcoming. In contradistinction to this report we here show that the level of the principal transcript of FPGS is down-regulated as no specific band could be observed in these cell lines upon Northern blot analysis (Fig. 4A) . Instead of a discrete principal transcript band, these antifolate-resistant cells exhibited a smear extending for several hundreds of base pairs insinuating the existence of multiple FPGS transcripts differing in length, thereby
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In order to explore the possibility of the occurrence of splicing defects in the FPGS transcript in the clinical setting, we obtained 13 RNA samples from 8 different ALL patients, 5 of which were matched specimens obtained both at diagnosis and relapse. PCR amplification of a region of the FPGS transcript encompassing exons 9-13 established exon12 skipping in one relapse specimen (Fig. 5A, lane 3) ; the ratio between the relatively low level of the 300bp PCR product reflecting exon 12 skipping and the high level of the normal (i.e.
properly spliced) 450bp product was found to be in a good concordance with the ratio of leukemic cells vs. normal leukocytes in the bone marrow from which the RNA sample was derived (i.e. patchy infiltration of leukemia cells among normal hematopoietic cells in a normocellular bone marrow). Taking into consideration the fact that complete remission (CR) is determined in the presence of less than 5% blasts in a normocellular bone marrow, patients with a smaller extent of disease might be erroneously determined as achieving a promising CR. Interestingly, 93% of all adult ALL patients achieve CR according to these criteria, whereas less than 40% eventually remain free of disease 24 . Hence, a relatively low level of the aberrant PCR product reflects the poor ratio of blast cells to normal cells, rather than reflecting mere low levels of the aberrantly spliced FPGS transcript relative to the normal transcript. To corroborate these findings, a second diagnostic PCR was performed that exclusively amplified the aberrant FPGS transcript that lacks exon 12 (Fig. 5B) ; this sensitive PCR approach allowed us to positively identify two additional ALL diagnosis specimens that also contained aberrant FPGS transcripts lacking exon 12. A second specimen obtained at diagnosis (D5) (Fig 5B, lane 10) exhibited very low levels of the aberrant FPGS transcript which was absent at the time of relapse (Fig 5B, lane 11) , whereas specimen D8 (Fig 5B, For personal use only. on September 14, 2017. by guest www.bloodjournal.org From all sizes of PCR fragments are depicted in Table 3 . 
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